Sciencast Management LP Takes $486,000 Position in Integra Lifesciences Holdings Corp (NASDAQ:IART)

Sciencast Management LP acquired a new stake in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 10,428 shares of the life sciences company’s stock, valued at approximately $486,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in IART. Oppenheimer Asset Management Inc. bought a new position in shares of Integra Lifesciences during the first quarter worth about $54,000. First Horizon Advisors Inc. increased its stake in shares of Integra Lifesciences by 70.5% in the first quarter. First Horizon Advisors Inc. now owns 1,410 shares of the life sciences company’s stock valued at $62,000 after purchasing an additional 583 shares during the period. Pearl River Capital LLC bought a new stake in shares of Integra Lifesciences during the first quarter valued at approximately $100,000. Acadian Asset Management LLC acquired a new position in shares of Integra Lifesciences during the first quarter worth approximately $120,000. Finally, Aigen Investment Management LP bought a new position in Integra Lifesciences in the 1st quarter worth approximately $140,000. Hedge funds and other institutional investors own 83.66% of the company’s stock.

IART has been the subject of a number of analyst reports. Zacks Investment Research upgraded Integra Lifesciences from a “sell” rating to a “hold” rating and set a $54.00 price target for the company in a research report on Friday, May 1st. BidaskClub downgraded shares of Integra Lifesciences from a “sell” rating to a “strong sell” rating in a report on Friday, July 10th. Piper Sandler reissued a “hold” rating and set a $58.00 target price on shares of Integra Lifesciences in a research note on Tuesday, April 7th. Citigroup started coverage on shares of Integra Lifesciences in a research report on Wednesday, May 27th. They set a “neutral” rating and a $54.00 price target on the stock. Finally, Wells Fargo & Co lowered their price objective on shares of Integra Lifesciences from $62.00 to $46.00 and set an “equal weight” rating on the stock in a research note on Monday, April 6th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $57.67.

IART opened at $47.75 on Friday. The firm has a market cap of $4.05 billion, a PE ratio of 154.03, a P/E/G ratio of 3.12 and a beta of 1.09. The company has a quick ratio of 2.72, a current ratio of 4.09 and a debt-to-equity ratio of 1.25. The business has a fifty day simple moving average of $48.12 and a 200-day simple moving average of $50.26. Integra Lifesciences Holdings Corp has a fifty-two week low of $34.21 and a fifty-two week high of $65.09.

Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Thursday, May 7th. The life sciences company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.63 by ($0.15). Integra Lifesciences had a return on equity of 15.98% and a net margin of 1.76%. The company had revenue of $354.30 million for the quarter, compared to analyst estimates of $353.15 million. During the same period last year, the firm earned $0.65 earnings per share. The firm’s revenue for the quarter was down 1.5% on a year-over-year basis. On average, equities research analysts anticipate that Integra Lifesciences Holdings Corp will post 1.73 EPS for the current fiscal year.

In related news, major shareholder Richard E. Caruso sold 600,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $48.47, for a total value of $29,082,000.00. Following the completion of the transaction, the insider now owns 163,668 shares of the company’s stock, valued at approximately $7,932,987.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Stuart Essig sold 2,087 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $52.07, for a total transaction of $108,670.09. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 663,995 shares of company stock worth $32,428,706. Corporate insiders own 4.30% of the company’s stock.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Story: Stock Market – What is a circuit breaker?

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.